Clinical Effect of Temozolomide-Based Chemotherapy in Poorly Differentiated Endocrine Carcinoma (PDEC) after Progression on First-Line Chemotherapy

被引：0
|
作者：
Welin, S.
Sorby, H.
Sebjornsen, S.
Knappskog, S.
Busch, C.
Oberg, K.
机构：
来源：
NEUROENDOCRINOLOGY | 2011年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：49 / 49
页数：1
相关论文
共 50 条
  • [1] Clinical Effect of Temozolomide-Based Chemotherapy in Poorly Differentiated Endocrine Carcinoma After Progression on First-Line Chemotherapy
    Welin, Staffan
    Sorbye, Halfdan
    Sebjornsen, Sigrunn
    Knappskog, Stian
    Busch, Christian
    Oberg, Kjell
    CANCER, 2011, 117 (20) : 4617 - 4622
  • [2] Cisplatin and Etoposide as First-line Chemotherapy for Poorly Differentiated Neuroendocrine Carcinoma of the Hepatobiliary Tract and Pancreas
    Iwasa, Satoru
    Morizane, Chigusa
    Okusaka, Takuji
    Ueno, Hideki
    Ikeda, Masafumi
    Kondo, Shunsuke
    Tanaka, Tsutomu
    Nakachi, Kohei
    Mitsunaga, Shuichi
    Kojima, Yasushi
    Hagihara, Atsushi
    Hiraoka, Nobuyoshi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (04) : 313 - 318
  • [3] Dacarbazine- or Temozolomide-Based Chemotherapy in Metastatic Digestive Neuroendocrine Carcinomas in Post First-line Chemotherapy: A Retrospective Multicentric Study of the French Group of Endocrine Tumours (GTE)
    Couronne, T.
    Fine, C.
    Hadoux, J.
    Lecomte, T.
    Lorcet, M.
    Vandevoorde, K.
    Forestier, J.
    Baudin, E.
    Lombard-Bohas, C.
    Walter, T.
    NEUROENDOCRINOLOGY, 2020, 110 : 185 - 185
  • [4] First-line chemotherapy vs salvage chemotherapy: Temozolomide and GBM
    Costa, F.
    Caroli, M.
    Menghetti, C.
    Motta, F.
    Fornari, M.
    De Santis, A.
    NEURO-ONCOLOGY, 2006, 8 (04) : 349 - 349
  • [5] First-Line Chemotherapy With Capecitabine and Temozolomide in Patients With Metastatic Pancreatic Endocrine Carcinomas
    Strosberg, Jonathan R.
    Fine, Robert L.
    Choi, Junsung
    Nasir, Aejaz
    Coppola, Domenico
    Chen, Dung-Tsa
    Helm, James
    Kvols, Larry
    CANCER, 2011, 117 (02) : 268 - 275
  • [6] Cisplatin plus etoposide as first-line chemotherapy for poorly-differentiated neuroendocrine carcinoma of the hepatobiliary and pancreatic region
    Iwasa, S.
    Morizane, C.
    Okusaka, T.
    Ueno, H.
    Ikeda, M.
    Kondo, S.
    Kojima, Y.
    Hagihara, A.
    Hiraoka, N.
    EJC SUPPLEMENTS, 2009, 7 (02): : 396 - 396
  • [7] Synergistic anticancer effect of acteoside and temozolomide-based glioblastoma chemotherapy
    Hwang, Tae Woong
    Kim, Dong Hun
    Kim, Da Bi
    Jang, Tae Won
    Kim, Gun-Hwa
    Moon, Minho
    Yoon, Kyung Ah
    Choi, Dae Eun
    Park, Jae Ho
    Kim, Jwa-Jin
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2019, 43 (03) : 1478 - 1486
  • [8] The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma
    Bafaloukos, D
    Tsoutsos, D
    Fountzilas, G
    Linardou, H
    Christodoulou, C
    Kalofonos, HP
    Briassoulis, E
    Panagiotou, P
    Hatzichristou, H
    Gogas, H
    MELANOMA RESEARCH, 2004, 14 (04) : 289 - 294
  • [9] Fotemustine as rescue therapy in recurrent or progressive glioblastoma after first-line temozolomide chemotherapy
    Lolli, Ivan
    Divella, Rosa
    Silvano, Giovanni
    Finamore, Simona
    Ercolino, Letizia
    Ronco, Michele
    Ciappetta, Pasqualino
    Troccoli, Giuseppe
    ANNALS OF ONCOLOGY, 2007, 18 : 64 - 64
  • [10] Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy
    Tassinari, Elisa
    Mollica, Veronica
    Nuvola, Giacomo
    Marchetti, Andrea
    Rosellini, Matteo
    Massari, Francesco
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 1945 - 1960
12345